Interventions for Tuberculosis Control and Elimination 2002

1152. Suzuki K, Tsuyuguchi K, Matsumoto H, Yamamoto T, Hashimoto T, Tanaka T,
Amitani R, Kuze F. Activity of KRM 1648 or rifabutin alone or in combination
with clarithromycin against Mycobacterium avium complex in human alveolar
macrophages. Int J Tuberc Lung Dis 1997; 1: 460-7.
1153. Roussel G, Igual J. Clarithromycin with minocyclin and clofazimine for
Mycobacterium avium intracellulare complex lung disease in patients without the
acquired immunodeficiency syndrome. Int J Tuberc Lung Dis 1998; 2: 462-70.
1154. Ward TT, Rimland D, Kauffman C, Huycke M, Evans TG, Heifets L.
Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin
plus ethambutol as therapy for Mycobacterium avium complex bacteremia in
patient with human immunodeficiency virus infection.
27: 1278-85.
Clin Infect Dis 1998;
1155. Truffot-Pernot C, Lounis N, Grosset JH, Ji B. Clarithromycin is inactive against
Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39: 2827-8.
1156. Dautzenberg B, Truffot C, Legris S, Meyohas MC, Berlie HC, Mercat A,
Chevret S, Grosset J. Activity of clarithromycin against Mycobacterium avium
infection in patients with the acquired immune deficiency syndrome. A controlled
clinical trial. Am Rev Respir Dis 1991; 144: 564-9.
1157. Bosi S, Da Ros T, Castellano S, Banfi E, Prato M. Antimycobacterial activity
of ionic fullerene derivatives. Bioorganic Med Chem Lett 2000; 10: 1043-5.
1158. Agrawal KC, Bears KB, Sehgal RK, Brown JN, Rist PE, Rupp WD. Potential
radiosensitizing agents. Dinitroimidazoles. J Med Chem 1979; 22: 583-5.
1159. Nagarajan K, Shankar RG, Rajapa S, Shenoy SJ, Costa-Pereira R.
Nitroimidazoles XXI 2,3-dihydro-6-nitroimidazo [2,1-b] oxazoles with antitubercular
activity. Eur J Med Chem 1989; 24: 631-3.
1160. Walsh JS, Wang R, Bagan E, Wang CC, Wislocki P, Miwa GT. Structural
alterations that differentially affect the mutagenic and antitrichomonal activities
of 5-nitroimidazoles. J Med Chem 1987; 30: 150-6.
1161. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM,
Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN,
Kreiswirth BN, Barry CE, Baker WR. A small-molecule nitroimidazopyran drug
candidate for the treatment of tuberculosis. Nature 2000; 405: 962-6.
1162. Stewart GR, Ehrt S, Riley LW, Dale JW, McFadden J. Deletion of the putative
antioxidant noxR1 does not alter the virulence of Mycobacterium tuberculosis
H37Rv. Tuber Lung Dis 2000; 80: 237-42.
1163. Slayden RA, Lee RE, Armour JW, Cooper AM, Orme IM, Brennan PJ,
Besra GS. Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid
and mycolic acid synthesis. Antimicrob Agents Chemother 1996; 40: 2813-9.
1164. Murugasu-Oei B, Dick T. Bactericidal activity of nitrofurans against growing
and dormant Mycobacterium bovis BCG.
917-9.
J Antimicrob Chemother 2000; 46:
247